NEW YORK (AP) — A major generic drugmaker has paid Bristol-Myers Squibb Co. and Sanofi SA more than $445 million to end a decade-long patent infringement case over blockbuster blood thinner Plavix, the world's second-best-selling drug.
Apotex Corp., Canada's biggest drugmaker, has paid the two brand-name drugmakers $442.2 million in damages for selling a generic version of Plavix in 2006.
Apotex launched its copycat version while it was still in a court dispute with Bristol and Sanofi, partners who jointly market Plavix. Apotex argued at the time that key patents on Plavix were invalid, doing what's called an "at-risk launch" of its generic version of Plavix.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
